Physician profile
Luke Noronha
NPI 1730139940
$1,783.14
in general payments reported to CMS, 2019-2025
17 companies · $579 in 2025
The $579 reported for 2025 was more than what 80% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $15.61 · 2021: $57.54 · 2022: $113 · 2023: $620 · 2024: $255 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $405.38 | 2023-2025 | Dupixent |
| Alcresta Therapeutics, INC. | $290.64 | 2023-2025 | Relizorb |
| Vertex Pharmaceuticals Incorporated | $206.29 | 2019-2024 | |
| Genzyme Corporation | $174.45 | 2023-2025 | |
| Abbvie INC. | $168.33 | 2019-2021 | |
| Mylan Specialty L.P. | $99.37 | 2022 | |
| Pharming Healthcare, INC. | $73.26 | 2023 | Joenja |
| Ucb, INC. | $64.72 | 2023-2025 | Briviact, Fintepla |
| Acadia Pharmaceuticals INC | $60.21 | 2024 | Daybue |
| Ascendis Pharma Endocrinology INC | $59.77 | 2024-2025 | Skytrofa |
| Sk Life Science, INC. | $49.42 | 2023-2024 | |
| Qol Medical, LLC | $25.42 | 2023 | Sucraid |
| Sanofi-Aventis U.S. LLC | $24.34 | 2025 | |
| Tolmar, INC. | $23.69 | 2023 | |
| Mirum Pharmaceuticals, INC. | $22.48 | 2025 | Livmarli |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $18.61 | 2025 | |
| Nestle Healthcare Nutrition INC. | $16.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Noronha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.